Health-Related Quality-of-Life Findings for the Prostate Cancer Prevention Trial | Zendy

Carol M. Moinpour | Zendy; Amy K. Darke | Zendy; Gary Donaldson | Zendy; Duane Cespedes | Zendy; Chris R. Johnson | Zendy; Patricia A. Ganz | Zendy; Donald L. Patrick | Zendy; John E. Ware | Zendy; Sally A. Shumaker | Zendy; Frank L. Meyskens | Zendy; Ian M. Thompson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Health-Related Quality-of-Life Findings for the Prostate Cancer Prevention Trial

Author(s) -

Carol M. Moinpour,

Amy K. Darke,

Gary Donaldson,

Duane Cespedes,

Chris R. Johnson,

Patricia A. Ganz,

Donald L. Patrick,

John E. Ware,

Sally A. Shumaker,

Frank L. Meyskens,

Ian M. Thompson

Publication year - 2012

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djs359

Subject(s) - finasteride , prostate cancer , medicine , quality of life (healthcare) , randomized controlled trial , prostate , placebo , cancer , oncology , gynecology , alternative medicine , nursing , pathology

The Prostate Cancer Prevention Trial (PCPT)-a randomized placebo-controlled study of the efficacy of finasteride in preventing prostate cancer-offered the opportunity to prospectively study effects of finasteride and other covariates on the health-related quality of life of participants in a multiyear trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research